1、Hotline: 400-820-3792Inhibitors Agonists Screening Librarieswww.MedChemELGD-6972Cat. No.: HY-12525CAS No.: 1207989-09-0分式: CHNOS分量: 702.9作靶點: Glucagon Receptor作通路: GPCR/G Protein儲存式: Powder -20C 3 years4C 2 yearsIn solvent -80C 6 months-20C 1 month溶解性數據體外實驗 DMSO : 31 mg/mL (44.10 mM)* means soluble,

2、 but saturation unknown.Mass Solvent1 mg 5 mg 10 mg Concentration制備儲備液1 mM 1.4227 mL 7.1134 mL 14.2268 mL5 mM 0.2845 mL 1.4227 mL 2.8454 mL10 mM 0.1423 mL 0.7113 mL 1.4227 mL請根據產品在不同溶劑中的溶解度，選擇合適的溶劑配制儲備液，并請注意儲備液的保存式和期限。BIOLOGICAL ACTIVITY物活性 LGD-6972種胰糖素受體拮抗劑。體內研究LGD-6972 has linear plasma pharmacoki

3、netics consistent with once daily dosing that is comparable inhealthy and T2DM subjects. Dose-dependent decreases in fasting plasma glucose are observed in all groupswith a maximum of 3.15 mM (56.8 mg/dL) on day 14 in T2DM subjects. LGD-6972 also reduces plasmaglucose in the postprandial state. Dose

4、-dependent increases in fasting plasma glucagon are observed, but1/2 Master of Small Molecules 您邊的抑制劑師www.MedChemEglucagon levels decrease and insulin levels increase after an oral glucose load in T2DM subjects. LGD-6972is well tolerated at the doses tested without dose-related or clinically meaning

5、ful changes in clinicallaboratory parameters. No subject experiences hypoglycaemia 1.REFERENCES1. Vajda EG, et al. Pharmacokinetics and pharmacodynamics of single and multiple doses of the glucagon receptor antagonist LGD-6972in healthy subjects and subjects with type 2 diabetes mellitus. Diabetes Obes Metab. 2017 Jan;19(1):24-32.McePdfHeightCaution: Product has not been fully validated for medical applications.For research use only.Tel: 400-820-3792; 0